Stock-Based Compensation

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Note 10 — Stock-Based Compensation

Stock compensation consisted of the following:

		Years Ended December 31,
		2020		2019
		(In millions)
Stock compensation expense	$	—	$	—

The 2011 Incentive Plan was approved and adopted by our shareholders on May 4, 2011 and became effective immediately. The 2011 Incentive Plan was amended and approved by our shareholders on May 8, 2013. The 2011 Incentive Plan permits the grant of stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units, dividend equivalents, performance awards, stock awards and other stock-based awards. The aggregate number of shares of our common stock that may be issued under all stock-based awards made under the 2011 Incentive Plan is 4,671. The number of shares available for awards, as well as the terms of outstanding awards, is subject to adjustments as provided in the 2011 Incentive Plan for stock splits, stock dividends, recapitalization and other similar events. Awards may be granted under the 2011 Incentive Plan until the earlier to occur of May 3, 2021 or the date on which all shares available for awards under the 2011 Incentive Plan have been granted; provided, however, that incentive stock options may not be granted after February 10, 2021.

Stock-based compensation awards issued under the 2011 Incentive Plan generally have a term of ten years and, for employees, vest over a three-year period. Exercise prices of awards issued under these plans are equal to the fair value of the Company’s stock on the date of grant.

As of December 31, 2020, there were 1,360 outstanding stock-based compensation awards under the 2011 Incentive Plan. As of December 31, 2020, there were no shares available for grant under our 2011 Incentive Plan.

Stock Options

The following table summarizes our stock option activity:

	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Outstanding December 31, 2018		113		$	16,734.00		0.2
Forfeited		(113	)		16,734.00
Granted		1,360			106.00
Outstanding December 31, 2019		1,360		$	106.00		9.7
Granted		—			—
Outstanding December 31, 2020		1,360		$	106.00		8.7
Exercisable as of December 31, 2020		873		$	106.00		8.7

The Company did not grant any options during the year ended December 31, 2020, and granted 1,360 options during the year ended December 31, 2019. There were no options exercised in 2019 or 2020. As of December 31, 2020 there are 1,360 shares outstanding and 873 shares are exercisable. The aggregate intrinsic value of all outstanding stock options was $0.0 million as of December 31, 2020.

Total stock-based compensation expense associated with stock options related to continuing operations recognized in our Consolidated Statements of Operations for the years ended December 31, 2020 and 2019 was $0.0 million. As of December 31, 2020, unrecognized compensation expense related to outstanding stock options was immaterial.

No related stock-based compensation was capitalized as part of an asset for the years ended December 31, 2020 or 2019.

Restricted Stock

The following table summarizes our restricted stock activity:

	Restricted Stock			Weighted Average Grant Date Fair Value Per Share
Nonvested as of December 31, 2018		150		$	1,406.00
Vested		(75	)		1,406.00
Forfeited		(75	)		1,406.00
Nonvested as of December 31, 2019		—		$	—
Nonvested as of December 31, 2020		—		$	—

No shares of restricted stock were granted during the years ended December 31, 2019 or 2020.

The total fair value of shares that vested during the years 2020 and 2019 was $0.0 million and $0.1 million, respectively.

Total stock-based compensation expense associated with restricted stock relating to continuing operations recognized in our Consolidated Statements of Operations for the years ended December 31, 2020 and 2019 was $0.0 million. As of December 31, 2020, the Company does not have any outstanding restricted stock or related unrecognized compensation expense.

No related stock-based compensation was capitalized as part of an asset for the years ended December 31, 2020 or 2019.